Bicyclic nucleoside inhibitors of varicella-zoster virus: 5'-chloro and 3'-chloro derivatives. 2003

G Luoni, and C McGuigan, and G Andrei, and R Snoeck, and E De Clercq, and J Balzarini
Welsh School of Pharmacy, Cardiff University, Cardiff, UK. luonig@cf.ac.uk

We have recently discovered bicyclic furopyrimidines as potent and selective inhibitors of VZV. In order to investigate the structural requirements for antiviral activity we have succesfully synthesised some 3'-chloro and 5'-chloro derivatives. The compounds have been tested against VZV and CMV, but displayed no significant in vitro activity.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D011741 Pyrimidine Nucleosides Pyrimidines with a RIBOSE attached that can be phosphorylated to PYRIMIDINE NUCLEOTIDES. Nucleosides, Pyrimidine
D003587 Cytomegalovirus A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS. Herpesvirus 5, Human,Human Herpesvirus 5,Salivary Gland Viruses,HHV 5,Herpesvirus 5 (beta), Human,Cytomegaloviruses,Salivary Gland Virus,Virus, Salivary Gland,Viruses, Salivary Gland
D005459 Fluorides Inorganic salts of hydrofluoric acid, HF, in which the fluorine atom is in the -1 oxidation state. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Sodium and stannous salts are commonly used in dentifrices. Fluoride
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D001643 Bridged Bicyclo Compounds Saturated alicyclic hydrocarbon molecules consisting of two rings that have two non-adjacent atoms in common. Bicyclo Compounds,Bicyclo Compounds, Bridged
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014645 Herpesvirus 3, Human The type species of VARICELLOVIRUS causing CHICKENPOX (varicella) and HERPES ZOSTER (shingles) in humans. Chickenpox Virus,Herpes zoster Virus,Ocular Herpes zoster Virus,VZ Virus,Varicella-Zoster Virus,HHV-3,Herpesvirus 3 (alpha), Human,Herpesvirus Varicellae,Human Herpesvirus 3,Chickenpox Viruses,Herpes zoster Viruses,VZ Viruses,Varicella Zoster Virus,Varicella-Zoster Viruses,Varicellae, Herpesvirus
D014994 Xylose D-Xylose,D Xylose
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs

Related Publications

G Luoni, and C McGuigan, and G Andrei, and R Snoeck, and E De Clercq, and J Balzarini
May 2001, Antiviral chemistry & chemotherapy,
G Luoni, and C McGuigan, and G Andrei, and R Snoeck, and E De Clercq, and J Balzarini
January 2003, Nucleosides, nucleotides & nucleic acids,
G Luoni, and C McGuigan, and G Andrei, and R Snoeck, and E De Clercq, and J Balzarini
July 2002, The Journal of antimicrobial chemotherapy,
G Luoni, and C McGuigan, and G Andrei, and R Snoeck, and E De Clercq, and J Balzarini
September 2002, Antiviral chemistry & chemotherapy,
G Luoni, and C McGuigan, and G Andrei, and R Snoeck, and E De Clercq, and J Balzarini
January 2001, Nucleosides, nucleotides & nucleic acids,
G Luoni, and C McGuigan, and G Andrei, and R Snoeck, and E De Clercq, and J Balzarini
April 2009, Bioorganic & medicinal chemistry,
G Luoni, and C McGuigan, and G Andrei, and R Snoeck, and E De Clercq, and J Balzarini
February 2001, Bioorganic & medicinal chemistry letters,
G Luoni, and C McGuigan, and G Andrei, and R Snoeck, and E De Clercq, and J Balzarini
November 2000, Antiviral chemistry & chemotherapy,
G Luoni, and C McGuigan, and G Andrei, and R Snoeck, and E De Clercq, and J Balzarini
January 2003, Nucleosides, nucleotides & nucleic acids,
G Luoni, and C McGuigan, and G Andrei, and R Snoeck, and E De Clercq, and J Balzarini
June 2000, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!